17-Jul-2026
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
PRNewswire (Thu, 16-Jul 8:00 AM ET)
PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities
TipRanks (Wed, 15-Jul 6:47 AM ET)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Wed, 17-Jun 4:31 PM ET)
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
PRNewswire (Mon, 15-Jun 11:15 PM ET)
Market Chameleon (Mon, 15-Jun 3:34 AM ET)
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
PRNewswire (Mon, 15-Jun 7:01 AM ET)
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
PRNewswire (Thu, 7-May 4:01 PM ET)
PTC Therapeutics to Participate in Upcoming Investor Conferences
PRNewswire (Mon, 4-May 8:00 AM ET)
PRNewswire (Tue, 28-Apr 4:05 PM ET)
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
PRNewswire (Tue, 28-Apr 9:29 AM ET)
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
PTC Therapeutics trades on the NASDAQ stock market under the symbol PTCT.
As of July 17, 2026, PTCT stock price climbed to $78.59 with 568,220 million shares trading.
PTCT has a beta of 0.37, meaning it tends to be less sensitive to market movements. PTCT has a correlation of 0.01 to the broad based SPY ETF.
PTCT has a market cap of $6.52 billion. This is considered a Mid Cap stock.
Last quarter PTC Therapeutics reported $273 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.38.
In the last 3 years, PTCT traded as high as $90.87 and as low as $17.53.
The top ETF exchange traded funds that PTCT belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
PTCT has outperformed the market in the last year with a return of +61.9%, while the SPY ETF gained +19.5%. In the last 3 month period, PTCT beat the market returning +8.5%, while SPY returned +4.9%. However, in the most recent 2 weeks PTCT has underperformed the stock market by returning -5.7%, while SPY returned -0.2%.
PTCT support price is $76.34 and resistance is $80.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTCT shares will trade within this expected range on the day.